REG - Eco Animal Health Gp - Directorate Change

ECO Animal HealthAnnouncement

09/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220809:nRSI3220Va&default-theme=true

RNS Number : 3220V  Eco Animal Health Group PLC  09 August 2022

9 August 2022

ECO Animal Health Group plc

(''ECO", the "Company" or the "ECO Group") (AIM: EAH)

Directorate Change

ECO Animal Health plc announces today that Tony Rawlinson, Non-Executive
Director, has resigned from the Board to pursue other business opportunities,
with immediate effect.

Andrew Jones the Chairman of ECO Animal Health commented:

"Tony has been a Non-Executive Director at ECO Animal Health plc for nearly
eight years and has been involved in the development and implementation of
important changes in corporate governance and remuneration policy.  The Board
sincerely thanks him for his much-valued contribution and wish him well for
the future."

 

 

For further information please contact:

 ECO Animal Health Group plc                                     020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                    020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)       020 7496 3000

 Mark Taylor

 George Tzimas

 Investec (Joint Broker)                                         020 7597 5970

 Gary Clarence

 Brough Ransom

 Carlo Spingardi

 Peel Hunt LLP (Joint Broker)                                    020 7418 8900

 Dr Christopher Golden

 James Steel

 

 Equity Development  020 7065 2692

 Hannah Crowe

 Matt Evans

 

 About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUAPRUPPGMR